Anzeige
Mehr »
Sonntag, 31.05.2026 - Börsentäglich über 12.000 News
Der Markt schläft noch: Neben ACM explodiert die Lithium-Ressource um 650
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
29.05.26 | 18:20
27,600 Euro
+0,55 % +0,150
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
27,24027,68030.05.
27,31027,59029.05.

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer11
DiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::PLANNED REVISION OF CONSOLIDATED FINANCIAL STATEMENTS RELATED TO A SUBSEQUENT EVENT7
DiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::TAKEDA EXECUTIVE COMPENSATION OVERVIEW9
DiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::CEO-ELECT SHAREHOLDER LETTER 20266
DiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::OTHER ITEMS WHICH ARE PROVIDED ELECTRONICALLY FOR THE 150TH ORDINARY GENERAL MEETING OF SHAREHOLDERS3
DiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::NOTICE OF CONVOCATION OF THE 150TH ORDINARY GENERAL MEETING OF SHAREHOLDERS4
22.05.Takeda Vows Appeal of $885M Jury Verdict in 'Pay-for-Delay' Antitrust Case4
22.05.Should You Buy KROS After Q1 Miss and Takeda Deal Reset?7
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
22.05.Fierce Pharma Asia-Merck-Kelun ADC's triple wins; Tools in China licensing deals; Takeda's $885M antitrust loss7
20.05.Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict19
19.05.Takeda übertrifft Gewinnerwartungen im vierten Quartal 202520
19.05.Jury Hits Takeda With $885 Million Antitrust Verdict7
19.05.Takeda slapped with $885M verdict in pay-for-delay antitrust case11
19.05.Jury finds Takeda liable for $885m in pay-for-delay lawsuit17
19.05.EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results1.765EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Other Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA (lubiprostone)...
► Artikel lesen
19.05.Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results409TOKYO (dpa-AFX) - Takeda Pharmaceutical Co. Ltd. (TAK) said Tuesday a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the AMITIZA...
► Artikel lesen
19.05.Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury7
19.05.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::JURY VERDICT IN AMITIZA ANTITRUST LITIGATION IN US & RELATED REVISION TO FY25 FINANCIAL RESULTS5
18.05.Takeda found guilty in 'pay-for-delay' scheme over Amitiza3
15.05.Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers15
Weiter >>
162 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1